Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive brea
 

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

More...